Analysts Offer Predictions for TSE:GUD Q1 Earnings

Knight Therapeutics Inc. (TSE:GUD) – Equities researchers at Stifel Canada issued their Q1 2025 earnings estimates for shares of Knight Therapeutics in a note issued to investors on Monday, March 24th. Stifel Canada analyst J. Keywood expects that the company will post earnings per share of $0.03 for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Stifel Canada also issued estimates for Knight Therapeutics’ Q3 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.04 EPS and FY2026 earnings at $0.21 EPS.

Several other analysts also recently commented on GUD. Research Capitl raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th. Stifel Nicolaus raised their price target on Knight Therapeutics from C$6.25 to C$7.45 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Canaccord Genuity Group lowered Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 21st. One research analyst has rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of C$7.48.

Knight Therapeutics Stock Up 0.5 %

Shares of TSE:GUD opened at C$6.04 on Thursday. The company has a 50 day moving average price of C$5.72 and a two-hundred day moving average price of C$5.59. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The company has a market capitalization of C$610.95 million, a PE ratio of -20.16, a PEG ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics has a 52 week low of C$5.09 and a 52 week high of C$6.45.

Insider Buying and Selling

In other Knight Therapeutics news, insider Sime Armoyan sold 92,200 shares of Knight Therapeutics stock in a transaction on Monday, March 17th. The shares were sold at an average price of C$6.15, for a total value of C$567,030.00. Over the last three months, insiders sold 3,143,300 shares of company stock worth $19,733,740. 45.62% of the stock is owned by corporate insiders.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.